|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Dipyridamole#Use in Specific Populations]] |
| | |
| {{Dipyridamole}}
| |
| | |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Use In Specific Populations==
| |
| | |
| ===Pregnancy===
| |
| | |
| '''Teratogenic Effects: Pregnancy Category B'''
| |
| | |
| Reproduction studies have been performed in mice, rabbits and rats at oral dipyridamole doses of up to 125 mg/kg, 40 mg/kg and 1000 mg/kg, respectively (about 1 ½, 2 and 25 times the maximum recommended daily human oral dose, respectively, on a mg/m2 basis) and have revealed no evidence of harm to the fetus due to dipyridamole. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, PERSANTINE tablets should be used during pregnancy only if clearly needed.
| |
| | |
| ===Nursing Mothers===
| |
| | |
| As dipyridamole is excreted in human milk, caution should be exercised when PERSANTINE tablets are administered to a nursing woman.
| |
| | |
| ===Pediatric Use===
| |
| | |
| Safety and effectiveness in the pediatric population below the age of 12 years have not been established.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PERSANTINE (DIPYRIDAMOLE) TABLET, COATED [BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ca68879c-0214-4d7c-93b0-bdaf8ef23f8e | publisher = | date = | accessdate = 7 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Antiplatelet drugs]]
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| | |
| [[Category:Drugs]]
| |
| | |
| {{WikiDoc Help Menu}}
| |
| | |
| {{WikiDoc Sources}}
| |